Marina Chiara Garassino to Biomarkers
This is a "connection" page, showing publications Marina Chiara Garassino has written about Biomarkers.
Connection Strength
0.340
-
Circulating Fatty Acid Profile as a Biomarker for Immunotherapy in Advanced Non-Small Cell Lung Cancer. Clin Lung Cancer. 2022 Nov; 23(7):e489-e499.
Score: 0.137
-
PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis. J Immunother Cancer. 2023 06; 11(6).
Score: 0.036
-
The EU-funded I3LUNG Project: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy. Clin Lung Cancer. 2023 06; 24(4):381-387.
Score: 0.036
-
Circulating CD81-expressing extracellular vesicles as biomarkers of response for immune-checkpoint inhibitors in advanced NSCLC. Front Immunol. 2022; 13:987639.
Score: 0.035
-
Prognostic role of neutrophil-to-lymphocyte ratio and EPSILoN score in advanced non-small-cell lung cancer patients treated with first-line chemo-immunotherapy. Future Oncol. 2022 Jul; 18(23):2593-2604.
Score: 0.034
-
Myeloid cell heterogeneity in lung cancer: implication for immunotherapy. Cancer Immunol Immunother. 2021 Sep; 70(9):2429-2438.
Score: 0.031
-
Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers. Lung Cancer. 2021 02; 152:165-173.
Score: 0.031